Course Overview

DSM-301: Disease Management (3 Credits)
Program(s): CMR and CPM

COURSE CONSULTANTS

FIFTH EDITION:

J. Lyle Bootman, PhD, ScD
Dean, College of Pharmacy
Professor of Pharmacy, Medicine, and Public Health

Executive Director of the Center for Health Outcomes and PharmacoEconomic (HOPE) Research
Arizona Health Sciences Center
The University of Arizona
Tucson, Arizona

Lesley Curtis, PhD
Assistant Research Professor
Center for Clinical and Genetic Economics
Director of CERTs Data Center
Duke Clinical Research Institute
Duke University Medical Center
Durham, North Carolina

Graduate Supplement
DSM-5301
To earn graduate-level credit, this supplement and course DSM-301 must be successfully completed.

Click here for more information about graduate-level credit.

Who Should Take This Course:
Sales representatives, managers, and others whose companies offer disease management programs, have products utilized in disease management programs, or work with healthcare providers who design and implement disease management programs.

Career Applications/Benefits:
Many pharmaceutical companies, pharmacy benefit management companies (PBMs), and private consulting companies have made a significant investment to develop and provide disease management services to healthcare organizations. Being able to demonstrate quality medical services is an important priority for managed care organizations (MCOs) seeking to gain a competitive edge in attracting new members, particularly the burgeoning senior market and employee health benefit contracts. This course will benefit those in pharmaceutical companies that have initiated disease management services focusing on specific diseases that complement their product line. Pharmaceutical therapies are often key components of disease management programs for conditions such as asthma, diabetes, and cardiovascular disease. Also, these types of programs are being widely discussed by healthcare providers, who may have questions or concerns about how disease management and associated clinical practice guidelines are being implemented.

Course Description:
This course is one of four foundation courses required by CMR Institute for certification. The course describes the key concepts of disease management and the basic components of successful disease management programs. It illustrates these components with realistic case scenarios. This course also describes the role of pharmaceutical companies in providing disease management services to healthcare organizations.

Related Courses:
• The 21st Century Physician
• Asthma: Approaches in Disease Management
• Cardiovascular Virtual Preceptorship
• Contemporary Pharmacoeconomics
• Diabetes: Approaches in Disease Management
• Diabetes Virtual Preceptorship
• The Formulary Process—Managing the Pharmacy Benefit
• The Managed Healthcare Market
• Oncology: Treatment and Management
• Outcomes: Measurement, Management, and Marketing

Chapter Content:

Chapter 1: Introduction to Disease Management
	Concepts of Disease Management Benefits of Disease Management
Chapter 2: Elements of Disease Management
	Elements of Disease Management Systems Population Demographics Clinical Practice Guidelines Intervention Techniques Monitoring Patient Data Performing Outcomes Assessment Summary of the Elements of Disease Management
Chapter 3: Managed Care and Disease Management Programs
	Continuous Quality Improvement Key Issues Federal and State Disease Management Programs
Chapter 4: Impact of Disease Management on the Pharmaceutical Industry
	The Pharmaceutical Industry and Disease Management Role of the Healthcare Representative

Learning Objectives:
Upon successful completion of this course, the student will be able to describe the factors that led to the implementation of disease management systems and the potential benefits of disease management; identify the key elements of comprehensive disease management systems; describe how disease management programs are being implemented in managed care organizations, discuss the impact of disease management systems on the pharmaceutical industry and the healthcare representative; and describe the strategies that pharmaceutical companies are developing to participate more fully in disease management.